Wegovy Maintenance: What Happens Long Term and When You Stop

Wegovy maintenance usually means continuing semaglutide at a dose you tolerate, most often 2.4mg once a week, after the initial weight loss has levelled off. The trial evidence is consistent: people who keep taking Wegovy tend to hold their weight loss, while people who stop tend to regain a substantial part of it within a year. That does not mean everyone must stay on it for life, but it does mean stopping should be a planned decision made with your prescriber, not something that happens by accident when a prescription runs out.

What "maintenance" means on Wegovy

Treatment with Wegovy has two broad phases. The first is the dose-escalation and weight-loss phase. You start at 0.25mg once weekly and step up every four weeks through 0.5mg, 1mg and 1.7mg to reach 2.4mg at around week 17. Weight loss is usually steepest during the first six to nine months and then slows. Our Wegovy dosing schedule guide explains the step-up in detail.

The second is the maintenance phase, when weight has largely plateaued and the aim shifts from losing weight to keeping it off and protecting the health gains that came with it, such as lower blood pressure, better blood glucose and improved mobility. In the large trials, most of the weight loss on semaglutide 2.4mg had happened by around week 60, with the curve flattening after that.

Maintenance is not a separate product or dose. In most cases it simply means continuing the dose that got you there. For some people that is a lower dose than 2.4mg because side effects limited escalation. For a smaller group, a prescriber may consider the higher 7.2mg dose (see below). The key point is that the plateau is not a sign the medicine has stopped working. It usually reflects a new balance between appetite, energy intake and a lower body weight, and the medicine is part of what holds that balance in place.

Why weight plateaus

As you lose weight, your body uses less energy at rest and during movement, and hormonal signals that drive hunger tend to increase. These adaptations are part of why weight regain is so common after any form of weight loss, including diet alone. Semaglutide acts on GLP-1 receptors in the brain and gut to reduce appetite and slow stomach emptying, which helps counter some of those signals. When the drug is removed, the counter-pressure goes too. Our guide to how Wegovy works covers the biology in more depth, and the weight loss plateau guide looks at what to do when progress stalls earlier than expected.

What the trials show about staying on Wegovy

Several trials help answer the question "what happens if I keep going?" The table below summarises the most relevant ones.

Figures are averages from trial populations, which received structured lifestyle support. Individual results vary widely.

STEP 4: the clearest test of continuing versus stopping

STEP 4 is the most direct evidence on maintenance. Around 900 adults with overweight or obesity (without diabetes) all received semaglutide, escalating to 2.4mg over 16 weeks and then staying on that dose to week 20. By then they had lost an average of about 10% of their body weight. They were then randomised: two-thirds continued semaglutide and one-third were switched, without knowing it, to placebo injections. Everyone continued with lifestyle support.

Over the next 48 weeks, the groups went in opposite directions. Those who continued semaglutide lost a further 7.9% on average. Those switched to placebo regained 6.9%. The difference was not subtle, and it appeared within weeks of switching. Blood pressure, waist size and other cardiometabolic measures also moved back towards baseline in the placebo group.

STEP 5 and SELECT: does the effect last?

A common worry is that the medicine "wears off". The longer trials suggest it generally does not, at least for the time studied. In STEP 5, weight loss at two years was very similar to what STEP 1 showed at 68 weeks, with most of the loss sustained through the second year.

SELECT followed more than 17,000 people with established cardiovascular disease and overweight or obesity for an average of more than three years. A later analysis published in Nature Medicine in 2024 reported that weight loss on semaglutide was maintained out to four years, at around 10% on average. SELECT was primarily a heart outcomes trial, and we cover it in detail in our Wegovy and heart health guide.

What happens when you stop Wegovy

Weight

The clearest data come from the STEP 1 extension. After 68 weeks of treatment, semaglutide and lifestyle support were both stopped, and a subset of participants were followed for another year. People who had taken semaglutide had lost an average of about 17% of their body weight during treatment. One year after stopping, they had regained about two-thirds of that, leaving them around 5–6% below their starting weight on average. The placebo group, by comparison, changed little.

So stopping did not usually take people all the way back to where they started within a year, but most of the benefit was lost, and the curve was still rising when follow-up ended. Similar patterns have been seen when tirzepatide is stopped (in SURMOUNT-4) and with older weight-loss medicines. Our dedicated guide to weight regain after stopping GLP-1 medication looks at the wider evidence.

Cardiometabolic markers

In the STEP 1 extension, improvements in blood pressure, cholesterol, blood glucose (HbA1c) and other markers also largely reversed towards baseline after stopping. This matters because, for many people, those markers are the real reason treatment was started. If you have prediabetes, high blood pressure or a history of heart disease, coming off Wegovy may mean other treatments need to be reviewed.

Appetite

Many people notice their appetite returning within a few weeks of the last injection. Semaglutide has a half-life of about a week, so it takes several weeks to clear completely, and the return of hunger is often gradual rather than sudden. People sometimes describe "food noise" coming back. This is an expected pharmacological effect, not a personal failing.

Side effects

Stopping Wegovy is not known to cause withdrawal symptoms, and you do not need to taper to avoid them. Gastrointestinal side effects usually settle as the drug leaves your system. If you restart later, however, you will usually need to start again at a lower dose and step up, because tolerance to the gastrointestinal effects is lost. Your prescriber will advise on this.

How long can you take Wegovy in the UK?

On the NHS

Under NICE TA875 (March 2023), semaglutide is recommended for weight management for a maximum of two years, within a specialist weight management service. The two-year limit reflected the evidence and economic modelling available at the time rather than a safety ceiling. NICE has since begun reviewing TA875, so the rules may change; check the NICE website for the current position. Separately, NICE TA1152 (May 2026) recommends semaglutide to reduce the risk of cardiovascular events in adults with established cardiovascular disease and a BMI of at least 27, and that guidance has a different purpose and different criteria. Our guide to Wegovy on the NHS explains both.

Privately

The UK licence (the SmPC) does not set a maximum duration. It does advise that treatment should be reviewed, and that if a person has not lost at least 5% of their initial body weight after six months on the treatment dose, a decision is needed about whether to continue, taking into account the overall clinical picture. Regulated private providers generally build in regular check-ins, weight verification and reviews of side effects before each supply. If you are comparing services, our provider comparison explains what each includes in its ongoing monitoring.

Cost over time

Long-term maintenance means a long-term cost if you are paying privately. What you pay depends on the dose, the provider's pricing model, whether consultations and delivery are included, and changes in manufacturer list prices. We do not quote prices in our guides because they change frequently, but our prices page is kept up to date and explains what is and is not included.

The 7.2mg dose and maintenance

In January 2026 the MHRA authorised a higher weekly dose of 7.2mg for adults with obesity (BMI of 30 or more) using Wegovy for weight management. It is not authorised for people with a BMI below 30 or for those using Wegovy solely to reduce cardiovascular risk. According to the MHRA and the patient leaflet, the 7.2mg dose is given as three separate 2.4mg injections on the same day, with a new needle each time and at least 5cm between sites, and it is only considered after at least four weeks on 2.4mg.

The evidence comes from the STEP UP trial (Lancet Diabetes & Endocrinology, 2025), in which adults with obesity lost an average of 20.7% of body weight at 72 weeks on 7.2mg, compared with 17.5% on 2.4mg and 2.4% on placebo (efficacy estimand). Gastrointestinal side effects and altered skin sensation (dysaesthesia) were more common at the higher dose.

For maintenance, the 7.2mg dose is likely to be relevant mainly to people who reached a plateau on 2.4mg with weight still in the obesity range and who tolerate the medicine well. It is not appropriate for everyone, and it is not currently covered by NICE guidance for NHS use. Check the current SmPC for the latest wording, and discuss it with your prescriber.

Stepping down: is a lower maintenance dose an option?

Some people ask whether they can reduce to a lower dose once they reach their goal, to cut side effects or cost. It is a reasonable question, but the honest answer is that the evidence is thin. The major trials compared full-dose continuation with stopping altogether; they did not test structured dose reduction. Small studies and clinical experience suggest some people can hold their weight on a lower dose, while others regain.

If you and your prescriber decide to try a lower dose, a sensible approach is to:

• Agree a clear plan, including what change in weight would prompt a rethink.
• Weigh yourself at consistent intervals and keep a simple log.
• Review again after a set period, such as three months.
• Keep up the habits that support weight maintenance (see below).

Do not reduce doses, split pens or space out injections on your own. Wegovy is designed for once-weekly dosing at the strengths in the SmPC.

Planning to stop: a practical checklist

People stop Wegovy for many reasons: reaching the NHS two-year limit, cost, side effects, pregnancy planning, upcoming surgery, or simply preferring to be off medication. Whatever the reason, it helps to plan.

Before you stop

1. Talk to your prescriber first. They can review your health conditions, other medicines and the likely impact of stopping.
2. Check what else depends on your weight. Blood pressure tablets, diabetes medicines and sleep apnoea treatment may need adjusting as weight changes in either direction.
3. Decide on a monitoring plan. Agree how often you will weigh yourself and what level of regain would prompt a conversation.
4. Consider alternatives. For some people, switching to another treatment may be an option. Our guides on switching from Wegovy to Mounjaro and oral GLP-1 tablets explain the considerations, though any switch is a prescriber's decision.

Habits that help after stopping

No lifestyle approach fully prevented regain in the trials, but the habits below are associated with better weight maintenance in general and support health regardless of weight:

• Protein at each meal. Adequate protein helps preserve muscle and supports fullness. See our guide to protein on GLP-1 medication.
• Strength training. Resistance exercise two or more times a week helps protect lean mass, which supports metabolic rate. Our preserving muscle guide has more.
• Regular physical activity. The UK Chief Medical Officers recommend at least 150 minutes of moderate activity a week for adults.
• Structured eating. Planning meals and keeping portions consistent can help as appetite returns.
• Sleep and stress. Poor sleep and high stress both tend to increase appetite.
• Self-monitoring. Regular weighing and noticing early regain allows earlier action.

If weight returns

Weight regain after stopping is common and reflects biology. If it happens, speak to your GP or prescriber. Options may include renewed lifestyle support, restarting treatment if you are eligible, or considering alternatives. Restarting usually means beginning again at a low dose.

Special situations

Pregnancy and fertility

The Wegovy SmPC advises stopping semaglutide at least two months before a planned pregnancy, because it stays in the body for several weeks. It should not be used in pregnancy or while breastfeeding. Weight loss can improve fertility in some people, so effective contraception matters during treatment. Our pregnancy and fertility guide covers this in detail.

Surgery and anaesthesia

Because semaglutide slows stomach emptying, there is a risk of stomach contents being inhaled during general anaesthesia or deep sedation. Tell your surgical and anaesthetic team you are taking Wegovy well in advance. They will advise whether and when to pause it. See our guide to GLP-1 medication before surgery.

Type 2 diabetes

If you have type 2 diabetes, stopping Wegovy may cause blood glucose to rise. Your diabetes team may need to adjust your other medicines.

Cardiovascular disease

If you are taking Wegovy partly to reduce cardiovascular risk, there is no evidence that the benefit seen in SELECT persists after stopping. Discuss any change with your cardiology team or GP.

Weighing up long-term treatment

Increasingly, obesity is described by clinicians and bodies such as NICE as a chronic, relapsing condition, similar in some ways to high blood pressure, where treatment often works while it is taken. That framing helps explain the trial results, but it does not settle every question. Long-term use brings its own considerations:

• Unknowns. Semaglutide has been used for type 2 diabetes since 2018 in the UK, and the SELECT and STEP 5 data extend to several years in obesity, but decades-long data do not yet exist.
• Side effects. Most gastrointestinal effects settle, but rare serious effects, such as pancreatitis and gallbladder problems, remain possible throughout treatment. See our Wegovy side effects guide.
• Muscle and bone. Rapid weight loss includes some lean tissue. Protein and resistance exercise matter more the longer treatment goes on.
• Cost and access. Private costs accumulate, and NHS access is time-limited under current guidance.
• Personal preference. Some people value being off medication even if it means some regain.

There is no single right answer. A good prescriber will talk through the trade-offs and revisit them at regular reviews. Our wider guide to long-term GLP-1 use brings together the evidence across medicines, and our Mounjaro maintenance guide covers the equivalent questions for tirzepatide.

When to speak to a professional

Speak to your GP, pharmacist or prescriber:

• Before stopping Wegovy, so they can review your other conditions and medicines.
• If you are planning a pregnancy or become pregnant.
• If you have surgery or a procedure with sedation coming up.
• If you are regaining weight quickly after stopping and feel you need support.
• If side effects are making it hard to continue, as dose changes or alternatives may help.
• If you have type 2 diabetes and notice symptoms of high blood sugar, such as increased thirst or passing more urine.

Seek urgent medical help (call NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, especially if it spreads to your back, with or without vomiting. This can be a sign of pancreatitis.
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes, which can indicate gallbladder problems.
• Persistent vomiting or diarrhoea with signs of dehydration, such as dizziness, very dark urine or passing little urine.
• Signs of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing.
• Sudden loss of vision or blurred vision in one eye.

For more on semaglutide injections, visit our Wegovy hub. Any decision about continuing, reducing or stopping Wegovy belongs to you and your prescriber together, based on your health, your goals and the latest guidance.